Dirk Arnold

8.6k total citations · 4 hit papers
108 papers, 4.1k citations indexed

About

Dirk Arnold is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Dirk Arnold has authored 108 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Oncology, 40 papers in Pulmonary and Respiratory Medicine and 20 papers in Surgery. Recurrent topics in Dirk Arnold's work include Colorectal Cancer Treatments and Studies (43 papers), Gastric Cancer Management and Outcomes (21 papers) and Pancreatic and Hepatic Oncology Research (16 papers). Dirk Arnold is often cited by papers focused on Colorectal Cancer Treatments and Studies (43 papers), Gastric Cancer Management and Outcomes (21 papers) and Pancreatic and Hepatic Oncology Research (16 papers). Dirk Arnold collaborates with scholars based in Germany, Spain and France. Dirk Arnold's co-authors include Daniel Hochhauser, Eric Van Cutsem, Anke Reinacher‐Schick, David McGuinness, Teresa Macarulla, Michele Reni, Hedy L. Kindler, Talia Golan, Gershon Y. Locker and Pascal Hammel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Dirk Arnold

95 papers receiving 4.1k citations

Hit Papers

Maintenance Olaparib for Germline BRCA -Mutated Metastati... 2018 2026 2020 2023 2019 2020 2018 2025 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
    2019 1.5k citations Talia Golan, Pascal Hammel et al. New England Journal of Medicine profile →
  2. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2020 736 citations Guillem Argilés, Josep Tabernero et al. Annals of Oncology profile →
  3. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2018 712 citations Arndt Vogel, Bruno Sangro et al. Annals of Oncology profile →
  4. Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2025 21 citations Ralf‐Dieter Hofheinz, Dirk Arnold et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dirk Arnold Germany 17 2.9k 1.1k 921 859 774 108 4.1k
Anke Reinacher‐Schick Germany 30 3.1k 1.1× 1.4k 1.3× 1.1k 1.2× 1.3k 1.5× 756 1.0× 158 4.7k
Jimmy J. Hwang United States 32 2.5k 0.9× 637 0.6× 814 0.9× 940 1.1× 780 1.0× 159 4.2k
Kanwal Raghav United States 33 2.9k 1.0× 1.1k 1.0× 1.2k 1.3× 628 0.7× 879 1.1× 203 4.3k
Bruce J. Giantonio United States 31 3.4k 1.1× 748 0.7× 1.6k 1.7× 1.3k 1.5× 729 0.9× 124 5.0k
Amit Mahipal United States 34 2.6k 0.9× 781 0.7× 1.1k 1.2× 1.3k 1.5× 1.6k 2.1× 266 4.4k
Jeremy Shapiro Australia 24 3.3k 1.1× 944 0.9× 1.5k 1.6× 907 1.1× 745 1.0× 142 4.6k
Chiara Carlomagno Italy 29 3.4k 1.2× 1.2k 1.1× 1.1k 1.2× 1.0k 1.2× 679 0.9× 99 4.7k
Susana Roselló Spain 31 2.3k 0.8× 859 0.8× 1.0k 1.1× 885 1.0× 686 0.9× 89 3.6k
John Hamm United States 22 4.0k 1.4× 1.3k 1.2× 1.6k 1.8× 1.1k 1.3× 624 0.8× 74 5.2k
Erika Martinelli Italy 23 2.2k 0.7× 577 0.5× 859 0.9× 629 0.7× 595 0.8× 86 3.4k

Countries citing papers authored by Dirk Arnold

Since Specialization
Citations

This map shows the geographic impact of Dirk Arnold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Arnold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Arnold more than expected).

Fields of papers citing papers by Dirk Arnold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Arnold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Arnold. The network helps show where Dirk Arnold may publish in the future.

Co-authorship network of co-authors of Dirk Arnold

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Arnold. A scholar is included among the top collaborators of Dirk Arnold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Arnold. Dirk Arnold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cutsem, Eric Van, Joëlle Collignon, Rikke Løvendahl Eefsen, et al.. (2024). Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer. Clinical Cancer Research. 30(23). 5293–5303. 2 indexed citations
3.
Stintzing, Sebastian, Jan Wierecky, Axel Wein, et al.. (2024). Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRC.. Journal of Clinical Oncology. 42(16_suppl). 3551–3551. 1 indexed citations
4.
Reimer, Peter, Valérie Vilgrain, Dirk Arnold, et al.. (2024). Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies. CardioVascular and Interventional Radiology. 47(3). 310–324. 2 indexed citations
5.
6.
Gerwert, Klaus, Frederik Großerueschkamp, Inke Sabine Feder, et al.. (2023). Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging. European Journal of Cancer. 182. 122–131. 18 indexed citations
7.
Geßler, Nele, Peter Wohlmuth, Jürgen Behr, et al.. (2023). High In-Hospital Mortality in SARS-CoV-2-Infected Patients with Active Cancer Disease during Omicron Phase of the Pandemic: Insights from the CORONA Germany Study. Oncology Research and Treatment. 46(5). 201–210. 3 indexed citations
8.
Stintzing, Sebastian, Jan Wierecky, Helmut Forstbauer, et al.. (2023). Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study.. Journal of Clinical Oncology. 41(4_suppl). 34–34. 1 indexed citations
9.
Lordick, Florian, Salah‐Eddin Al‐Batran, Dirk Arnold, et al.. (2023). German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer. Gastric Cancer. 27(1). 6–18. 3 indexed citations
10.
Kindler, Hedy L., Pascal Hammel, Michele Reni, et al.. (2022). Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Journal of Clinical Oncology. 40(34). 3929–3939. 120 indexed citations
11.
Reinacher‐Schick, Anke, et al.. (2022). Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice. Oncology Research and Treatment. 45(12). 752–763. 1 indexed citations
12.
Helmberger, Thomas, Pierleone Lucatelli, Philippe L. Pereira, et al.. (2022). Safety, Feasibility and Technical Considerations from a Prospective, Observational Study—CIREL: Irinotecan-TACE for CRLM in 152 Patients. Journal of Clinical Medicine. 11(20). 6178–6178. 8 indexed citations
13.
14.
Salvatore, Lisa, Emilio Bria, Isabella Sperduti, et al.. (2021). Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients’ data from 3 phase III studies. Cancer Treatment Reviews. 97. 102202–102202. 16 indexed citations
15.
Koessler, Thibaud, María Alsina, Dirk Arnold, et al.. (2021). Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. British Journal of Cancer. 125(7). 911–919. 3 indexed citations
16.
Fokas, Emmanouil, Michael Flentje, Rolf Sauer, et al.. (2020). Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. European Journal of Cancer. 144. 281–290. 13 indexed citations
17.
Arnold, Dirk, José Ignacio Bilbao, Geert Maleux, et al.. (2020). Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study. JMIR Research Protocols. 9(4). e16296–e16296. 5 indexed citations
18.
Argilés, Guillem, Josep Tabernero, Roberto Labianca, et al.. (2020). Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 31(10). 1291–1305. 736 indexed citations breakdown →
19.
Golan, Talia, Pascal Hammel, Michele Reni, et al.. (2019). Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer. New England Journal of Medicine. 381(4). 317–327. 1468 indexed citations breakdown →
20.
Hammel, P., Hedy L. Kindler, Michele Reni, et al.. (2019). Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Annals of Oncology. 30(12). 1959–1968. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anke Reinacher‐Schick Breakdown of academic impact, for papers by Jimmy J. Hwang Breakdown of academic impact, for papers by Kanwal Raghav Breakdown of academic impact, for papers by Bruce J. Giantonio Breakdown of academic impact, for papers by Amit Mahipal Breakdown of academic impact, for papers by Jeremy Shapiro Breakdown of academic impact, for papers by Chiara Carlomagno Breakdown of academic impact, for papers by Susana Roselló Breakdown of academic impact, for papers by John Hamm Breakdown of academic impact, for papers by Erika Martinelli
Rankless by CCL
2026